HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

C&D Expands Oral Care Portfolio, Acquires TheraBreath Mouthwash Brand In Latest Deal

Executive Summary

Church & Dwight anticipates 15% growth for TheraBreath mouthwash brand in 2022 on larger sizes and wider distribution, especially outside US. It plans to acquire the firm for around $580m cash and close the deal before end of year

You may also be interested in...



Distribution Drives C&D’s TheraBreath Growth Plan

In addition to advertising brand to consumers and expanding distribution,, C&D will promote TheraBreath dental hygienists along with to Waterpik power brushes and water-flossers.

Church & Dwight Meets Supply, Inflation Headwinds With Line Extensions, Price Increases

C&D executives didn’t downplay potential challenges during 2022 – including an expected $155m increase in costs from inflation – as they discussed the health, personal and household care manufacturer and marketer’s 2021 full-year and fourth-quarter results and its long-range plans.

US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption

Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020.  More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS151990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel